Can a gout drug protect kidneys in cancer patients?
NCT ID NCT04745910
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested pegloticase, a drug used for gout, in 10 cancer patients with high uric acid from tumor lysis syndrome. The goal was to see if it could quickly lower uric acid levels and protect kidney function. It was a small pilot trial to gather early data.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Pegloticase (a drug that breaks down uric acid)
- What this could lead to
- If it works, this could offer a new way to quickly lower uric acid and protect kidney function in cancer patients with tumor lysis syndrome.
- What could go wrong
- This is a very small pilot study with only 10 participants, so results may not apply to everyone. The drug may not work as expected or could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOPOIETIC AND LYMPHOID CELL NEOPLASM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new PET tracer reveal hidden immune clues in tumors?
- A hug in a blanket: could deep pressure calm cancer infusion anxiety?
- Could a strong social circle turn back the clock for transplant survivors?
- A virtual pharmacy visit may ease opioid fears for cancer patients
- Can meditation tame the Long-Term side effects of a stem cell transplant?
- Strumming through treatment: can ukulele lessons shield teen brains from Radiation's toll?